Experiment Number: 20006 - 04 Test Type: CHRONIC Route: GAVAGE Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Indole-3-carbinol CAS Number: 700-06-1 Date Report Requested: 06/15/2012 Time Report Requested: 12:41:17 First Dose M/F: 04/03/07 / 04/02/07 Lab: BAT

F1_M3

NTP Study Number:	C20006B
Lock Date:	03/08/2010
Cage Range:	ALL
Date Range:	ALL
Reasons For Removal:	ALL
Removal Date Range:	ALL
Treatment Groups:	Include ALL
Study Gender:	Both
TDMSE Version:	2.6.0.0_007
PWG Approval Date:	NONE

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Indole-3-carbinol

CAS Number: 700-06-1

Date Report Requested: 06/15/2012 Time Report Requested: 12:41:17 First Dose M/F: 04/03/07 / 04/02/07 Lab: BAT

B6C3F1 MICE MALE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	
Disposition Summary					
Animals Initially In Study	50	50	50	50	
Early Deaths					
Accidentally Killed				1	
Dosing Accident			1		
Moribund Sacrifice	17	12	11	9	
Natural Death	6	7	6	8	
Survivors					
Natural Death	1				
Terminal Sacrifice	26	31	32	32	
Animals Examined Microscopically	50	50	50	50	
ALIMENTARY SYSTEM					
Esophagus	(50)	(50)	(50)	(50)	
Mineralization	()	()	1 (2%)	()	
Gallbladder	(50)	(50)	(49)	(48)	
Atrophy	()	()	(- /	1 (2%)	
Inflammation, Suppurative				1 (2%)	
Intestine Large, Cecum	(50)	(50)	(50)	(50)	
Ulcer		1 (2%)		1 (2%)	
Intestine Large, Colon	(50)	(50)	(50)	(50)	
Inflammation, Chronic				1 (2%)	
Intestine Large, Rectum	(50)	(50)	(50)	(50)	
Inflammation, Chronic		1 (2%)			
Intestine Small, Duodenum	(50)	(50)	(50)	(50)	
Ulcer			(),	1 (2%)	
Epithelium, Atrophy				1 (2%)	
Intestine Small, Ileum	(50)	(50)	(50)	(50)	
Intestine Small, Jejunum	(50)	(50)	(49)	(50)	
Atrophy	1 (2%)	. ,	. ,		
Inflammation, Suppurative	1 (2%)				
Lymphangiectasis	1 (2%)				
Peyer's Patch, Hyperplasia	、 ,	1 (2%)	1 (2%)	1 (2%)	
Liver	(50)	(50)	(49)	(50)	

Species/Strain: MICE/B6C3F1

Route: GAVAGE

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Indole-3-carbinol

CAS Number: 700-06-1

Date Report Requested: 06/15/2012 Time Report Requested: 12:41:17 First Dose M/F: 04/03/07 / 04/02/07 Lab: BAT

6C3F1 MICE MALE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg
Basophilic Focus	2 (4%)	4 (8%)	2 (4%)	5 (10%)
Clear Cell Focus	7 (14%)	17 (34%)	22 (45%)	20 (40%)
Eosinophilic Focus	29 (58%)	35 (70%)	35 (71%)	33 (66%)
Fatty Change	29 (58%)	27 (54%)	28 (57%)	37 (74%)
Hepatodiaphragmatic Nodule		1 (2%)	· · ·	1 (2%)
Inflammation, Chronic		(),		1 (2%)
Mixed Cell Focus	1 (2%)	6 (12%)	6 (12%)	5 (10%)
Necrosis	3 (6%)	2 (4%)	2 (4%)	2 (4%)
Necrosis, Multifocal	1 (2%)			
Artery, Thrombosis				1 (2%)
Bile Duct, Hyperplasia				1 (2%)
Oval Cell, Hyperplasia				1 (2%)
Periportal, Fibrosis				1 (2%)
Mesentery	(7)	(3)	(2)	(2)
Fat, Necrosis	4 (57%)		2 (100%)	2 (100%)
Oral Mucosa	(0)	(1)	(0)	(2)
Pancreas	(50)	(50)	(50)	(50)
Inflammation, Chronic				2 (4%)
Acinus, Atrophy	1 (2%)		1 (2%)	
Duct, Cyst		1 (2%)		
Salivary Glands	(50)	(50)	(50)	(50)
Infiltration Cellular, Mononuclear Cell	23 (46%)	30 (60%)	27 (54%)	22 (44%)
Duct, Sublingual Gland, Hyperplasia			1 (2%)	
Stomach, Forestomach	(50)	(50)	(50)	(50)
Inflammation, Chronic		1 (2%)	4 (8%)	1 (2%)
Ulcer	6 (12%)	5 (10%)	7 (14%)	1 (2%)
Epithelium, Hyperplasia	2 (4%)	2 (4%)	4 (8%)	2 (4%)
Stomach, Glandular	(50)	(47)	(47)	(49)
Erosion	1 (2%)			
Inflammation, Chronic	1 (2%)	1 (2%)	18 (38%)	45 (92%)
Mineralization	5 (10%)	2 (4%)		
Pigmentation		1 (2%)	38 (81%)	48 (98%)
Epithelium, Atrophy				1 (2%)
Epithelium, Hyperplasia		1 (2%)	22 (47%)	40 (82%)
Tooth	(30)	(37)	(32)	(32)
Dysplasia	30 (100%)	36 (97%)	32 (100%)	32 (100%)

Test Type: CHRONIC Route: GAVAGE

Species/Strain: MICE/B6C3F1

HRONIC

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Indole-3-carbinol

CAS Number: 700-06-1

Date Report Requested: 06/15/2012 Time Report Requested: 12:41:17 First Dose M/F: 04/03/07 / 04/02/07 Lab: BAT

B6C3F1 MICE MALE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	
CARDIOVASCULAR SYSTEM					
Blood Vessel	(49)	(50)	(49)	(49)	
Adventitia, Pulmonary Vein, Infiltration Cellular, Polymorphonuclear	1 (2%)				
Aorta, Mineralization		1 (2%)			
Heart	(50)	(50)	(50)	(50)	
Cardiomyopathy	11 (22%)	7 (14%)	18 (36%)	8 (16%)	
Inflammation, Chronic	1 (2%)				
Artery, Inflammation, Chronic	1 (2%)				
Artery, Mineralization		1 (2%)			
Myocardium, Mineralization		3 (6%)		1 (2%)	
Valve, Inflammation				1 (2%)	
ENDOCRINE SYSTEM					
Adrenal Cortex	(50)	(50)	(50)	(50)	
Hyperplasia	1 (2%)			1 (2%)	
Hypertrophy		4 (8%)	2 (4%)		
Vacuolization Cytoplasmic		2 (4%)			
Adrenal Medulla	(50)	(50)	(50)	(50)	
Hyperplasia	2 (4%)		1 (2%)	2 (4%)	
Islets, Pancreatic	(50)	(50)	(50)	(50)	
Hyperplasia	1 (2%)		1 (2%)		
Parathyroid Gland	(48)	(44)	(48)	(44)	
Pituitary Gland	(50)	(50)	(50)	(50)	
Cyst	2 (4%)	1 (2%)	1 (2%)	1 (2%)	
Pars Intermedia, Hyperplasia		1 (2%)	. ,		
Thyroid Gland	(50)	(50)	(50)	(50)	
Inflammation, Chronic		. ,	. *	1 (2%)	
Follicle, Cyst	1 (2%)				
Follicle, Degeneration	. ,			1 (2%)	

Experiment Number: 20006 - 04 Test Type: CHRONIC Route: GAVAGE Species/Strain: MICE/B6C3F1	P03: INCIDENCE F	Date Report Requested: 06/15/20 Time Report Requested: 12:41:17 First Dose M/F: 04/03/07 / 04/02/07 Lab: BAT			
B6C3F1 MICE MALE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	
GENERAL BODY SYSTEM					
None					
GENITAL SYSTEM					
Coagulating Gland	(1)	(0)	(0)	(0)	
Epididymis	(50)	(50)	(50)	(50)	
Angiectasis				1 (2%)	
Granuloma Sperm				1 (2%)	
Infiltration Cellular, Mononuclear Cell	1 (2%)	6 (12%)	3 (6%)	5 (10%)	
Inflammation, Chronic		2 (4%)			
Preputial Gland	(50)	(50)	(50)	(50)	
Cyst	14 (28%)	10 (20%)	6 (12%)	6 (12%)	
Inflammation, Suppurative	2 (4%)				
Inflammation, Granulomatous	()	2 (4%)	()	2 (4%)	
Prostate	(50)	(50)	(50)	(50)	
Hyperplasia	2 (4%)		1 (2%)	1 (2%)	
Inflammation, Suppurative			1 (2%)		
Inflammation, Chronic	1 (2%)	(= =)		1 (2%)	
Seminal Vesicle	(50)	(50)	(50)	(50)	
Atrophy	1 (2%)	(=0)	(=0)	(=0)	
Testes	(50)	(50)	(50)	(50)	
Inflammation, Granulomatous	1 (2%)				
Inflammation, Chronic	1 (2%)				
Mineralization	1 (2%)		2 (60/)	2 (60/)	
Germinal Epithelium, Atrophy	2 (4%)		3 (6%)	3 (6%)	
HEMATOPOIETIC SYSTEM					
Bone Marrow	(50)	(50)	(50)	(50)	
Lymph Node	(2)	(2)	(0)	(4)	
Mediastinal, Hyperplasia		·	·	1 (25%)	
Pancreatic, Inflammation				1 (25%)	

Test Type: CHRONIC

Species/Strain: MICE/B6C3F1

Route: GAVAGE

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Indole-3-carbinol

CAS Number: 700-06-1

Date Report Requested: 06/15/2012 Time Report Requested: 12:41:17 First Dose M/F: 04/03/07 / 04/02/07 Lab: BAT

B6C3F1 MICE MALE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	
Pancreatic, Necrosis		1 (50%)			
Renal, Inflammation				1 (25%)	
Lymph Node, Mandibular	(50)	(50)	(50)	(50)	
Hyperplasia, Lymphoid		1 (2%)		1 (2%)	
Lymph Node, Mesenteric	(48)	(48)	(49)	(50)	
Hematopoietic Cell Proliferation	1 (2%)				
Hyperplasia, Lymphoid				2 (4%)	
Inflammation				1 (2%)	
Spleen	(50)	(50)	(50)	(50)	
Accessory Spleen			1 (2%)		
Atrophy				1 (2%)	
Hematopoietic Cell Proliferation	16 (32%)	16 (32%)	24 (48%)	20 (40%)	
Necrosis	1 (2%)				
Lymphoid Follicle, Atrophy	2 (4%)				
Thymus	(49)	(47)	(46)	(45)	
Atrophy	44 (90%)	44 (94%)	45 (98%)	39 (87%)	
Ectopic Parathyroid Gland		1 (2%)		1 (2%)	
INTEGUMENTARY SYSTEM					
Mammary Gland	(2)	(0)	(0)	(0)	
Skin	(50)	(50)	(50)	(50)	
Ulcer	3 (6%)	2 (4%)	3 (6%)	1 (2%)	
Subcutaneous Tissue, Inflammation, Acute	0 (070)	- (170)	1 (2%)	. (270)	
Subcutaneous Tissue, Inflammation, Chronic			2 (4%)		
			2 (470)		
MUSCULOSKELETAL SYSTEM					
Bone	(50)	(50)	(50)	(50)	
Hyperostosis	(00)	(00)	1 (2%)	1 (2%)	
Skeletal Muscle	(0)	(0)	(2)	(0)	
	(0)		(-)	(~)	

NERVOUS SYSTEM

Experiment Number: 20006 - 04 Test Type: CHRONIC Route: GAVAGE Species/Strain: MICE/B6C3F1	P03: INCIDENCE F	ATES OF NON-NEOP Indole-3 CAS Numb	Date Report Requested: 06/15/201 Time Report Requested: 12:41:17 First Dose M/F: 04/03/07 / 04/02/07 Lab: BAT		
B6C3F1 MICE MALE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	
Brain Meninges, Inflammation, Chronic	(50)	(50) 1 (2%)	(50)	(50)	
RESPIRATORY SYSTEM					
Lung Infiltration Cellular, Histiocyte	(50)	(50) 2 (4%)	(50)	(50) 1 (2%)	
Inflammation, Chronic Pigmentation, Hemosiderin		1 (2%) 1 (2%)	1 (2%)	1 (2%)	
Thrombosis			1 (2%)		
Alveolar Epithelium, Hyperplasia	3 (6%)	4 (8%)	5 (10%)		
Mediastinum, Inflammation, Granulomatous			1 (2%)		
Nose	(50)	(50)	(50)	(50)	
Foreign Body	3 (6%)	1 (2%)		3 (6%)	
Inflammation	15 (30%)	11 (22%)	12 (24%)	16 (32%)	
Polyp, Inflammatory	1 (2%)	2 (4%)	3 (6%)	1 (2%)	
Respiratory Metaplasia			1 (2%)		
Nerve, Atrophy		((22 ()		8 (16%)	
Nerve, Olfactory Epithelium, Atrophy	4 (00/)	1 (2%)	E (400/)	F (400()	
Olfactory Epithelium, Accumulation, Hyaline Droplet	4 (8%)	4 (8%)	5 (10%)	5 (10%)	
Olfactory Epithelium, Atrophy	3 (6%)	5 (10%)	11 (22%)	17 (34%)	
Olfactory Epithelium, Degeneration	1 (2%)	1 (2%)	4 (8%)	2 (4%)	
Olfactory Epithelium, Metaplasia, Squamous		· /	× ,	2 (4%)	
Olfactory Epithelium, Necrosis				6 (12%)	
Olfactory Epithelium, Respiratory Metaplasia	14 (28%)	14 (28%)	20 (40%)	27 (54%)	
Respiratory Epithelium, Accumulation, Hyaline Droplet	18 (36%)	34 (68%)	30 (60%)	26 (52%)	
Respiratory Epithelium, Hyperplasia	35 (70%)	40 (80%)	41 (82%)	45 (90%)	
Respiratory Epithelium, Metaplasia, Squamous				1 (2%)	
Respiratory Epithelium, Necrosis				2 (4%)	
Trachea	(50)	(50)	(50)	(50)	

SPECIAL SENSES SYSTEM

Species/Strain: MICE/B6C3F1

Route: GAVAGE

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Indole-3-carbinol

CAS Number: 700-06-1

Date Report Requested: 06/15/2012 Time Report Requested: 12:41:17 First Dose M/F: 04/03/07 / 04/02/07 Lab: BAT

B6C3F1 MICE MALE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	
Eye	(50)	(50)	(50)	(50)	
Phthisis Bulbi	1 (2%)	1 (2%)	()		
Anterior Chamber, Inflammation, Suppurative	· · · ·	1 (2%)		1 (2%)	
Cornea, Inflammation, Suppurative		1 (2%)			
Cornea, Inflammation, Chronic	2 (4%)	3 (6%)	2 (4%)	1 (2%)	
Optic Nerve, Infiltration Cellular, Mononuclear Cell				1 (2%)	
Harderian Gland	(50)	(50)	(50)	(50)	
Hyperplasia	1 (2%)	4 (8%)	5 (10%)	3 (6%)	
Inflammation, Suppurative	1 (2%)	1 (2%)			
Inflammation, Chronic		1 (2%)			
URINARY SYSTEM					
Kidney	(50)	(50)	(50)	(50)	
Infarct	3 (6%)	2 (4%)			
Inflammation, Acute		2 (4%)			
Inflammation, Chronic	1 (2%)			1 (2%)	
Metaplasia, Osseous	1 (2%)	1 (2%)	1 (2%)	1 (2%)	
Mineralization	4 (8%)	8 (16%)	1 (2%)	2 (4%)	
Nephropathy	42 (84%)	50 (100%)	45 (90%)	43 (86%)	
Thrombosis		1 (2%)			
Papilla, Necrosis	1 (2%)			1 (2%)	
Pelvis, Inflammation, Suppurative	2 (4%)	2 (4%)	1 (2%)		
Renal Tubule, Cyst	1 (2%)	3 (6%)	2 (4%)	2 (4%)	
Renal Tubule, Hyperplasia			1 (2%)		
Renal Tubule, Pigmentation	1 (2%)	1 (2%)	1 (2%)	5 (10%)	
Renal Tubule, Vacuolization Cytoplasmic	1 (2%)				
Urethra	(0)	(1)	(0)	(0)	
Inflammation, Acute		1 (100%)			
Urinary Bladder	(50)	(50)	(50)	(50)	
Hemorrhage		1 (2%)			
Inflammation, Chronic	1 (2%)	2 (4%)			

Experiment Number: 20006 - 04	P03: INCIDENCE RATE	TIC LESIONS BY A	NATOMIC SITE(a)	Date Report Requested: 06/15/2012	
Test Type: CHRONIC	Time Report Requested: 12:41:17				
Route: GAVAGE		CAS Number: 7	00-06-1		First Dose M/F: 04/03/07 / 04/02/07
Species/Strain: MICE/B6C3F1					Lab: BAT
B6C3F1 MICE MALE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	

*** END OF MALE ***

Species/Strain: MICE/B6C3F1

Route: GAVAGE

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Indole-3-carbinol

CAS Number: 700-06-1

Date Report Requested: 06/15/2012 Time Report Requested: 12:41:17 First Dose M/F: 04/03/07 / 04/02/07 Lab: BAT

B6C3F1 MICE FEMALE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg
Disposition Summary				
Animals Initially In Study	50	50	50	50
Early Deaths				
Dosing Accident	1			
Moribund Sacrifice	10	6	15	3
Natural Death	6	4	9	2
Survivors				
Moribund Sacrifice			1	
Terminal Sacrifice	33	40	25	45
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Esophagus	(50)	(50)	(50)	(50)
Gallbladder	(49)	(50)	(50)	(50)
Cyst	(/	1 (2%)	()	()
Inflammation, Chronic	1 (2%)	- ()		
Intestine Large, Cecum	(50)	(50)	(50)	(50)
Intestine Large, Colon	(50)	(50)	(50)	(50)
Intestine Large, Rectum	(50)	(50)	(50)	(50)
Intestine Small, Duodenum	(50)	(50)	(50)	(50)
Intestine Small, Ileum	(50)	(50)	(50)	(50)
Ulcer	1 (2%)	x - /	x - /	x - /
Epithelium, Hyperplasia	1 (2%)			
Intestine Small, Jejunum	(50)	(50)	(50)	(50)
Ulcer	1 (2%)	· /		. /
Liver	(50)	(50)	(50)	(50)
Angiectasis	1 (2%)	· · /		
Basophilic Focus	4 (8%)	6 (12%)	7 (14%)	5 (10%)
Clear Cell Focus	3 (6%)	2 (4%)	1 (2%)	1 (2%)
Eosinophilic Focus	16 (32%)	26 (52%)	26 (52%)	21 (42%)
Fatty Change	36 (72%)	39 (78%)	35 (70%)	40 (80%)
Hematopoietic Cell Proliferation	2 (4%)			
Hemorrhage		2 (4%)		
Hepatodiaphragmatic Nodule				1 (2%)

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Indole-3-carbinol

CAS Number: 700-06-1

Date Report Requested: 06/15/2012 Time Report Requested: 12:41:17 First Dose M/F: 04/03/07 / 04/02/07 Lab: BAT

36C3F1 MICE FEMALE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	
Hyperplasia, Lymphoid				1 (2%)	
Inflammation, Chronic		1 (2%)			
Mixed Cell Focus	2 (4%)	4 (8%)	5 (10%)	1 (2%)	
Necrosis	1 (2%)	1 (2%)	1 (2%)		
Bile Duct, Cyst		1 (2%)			
Centrilobular, Necrosis		· · ·	1 (2%)		
Mesentery	(3)	(7)	(7)	(6)	
Fat, Necrosis	3 (100%)	6 (86%)	7 (100%)	5 (83%)	
Pancreas	(50)	(50)	(50)	(50)	
Angiectasis		1 (2%)			
Inflammation, Chronic	1 (2%)	1 (2%)			
Acinus, Atrophy	· · ·	· /		1 (2%)	
Acinus, Hyperplasia	1 (2%)	2 (4%)	1 (2%)	· · ·	
Duct, Cyst	1 (2%)				
Salivary Glands	(50)	(49)	(50)	(50)	
Hyperplasia	1 (2%)				
Duct, Cyst	(),			1 (2%)	
Stomach, Forestomach	(50)	(50)	(50)	(50)	
Inflammation, Chronic	1 (2%)				
Ulcer	9 (18%)	4 (8%)	8 (16%)	3 (6%)	
Epithelium, Hyperplasia		()	1 (2%)	- ()	
Stomach, Glandular	(48)	(50)	(49)	(50)	
Erosion		()	(-)	1 (2%)	
Hyperplasia, Lymphoid	1 (2%)			. (_,,)	
Inflammation, Chronic		15 (30%)	29 (59%)	47 (94%)	
Mineralization	2 (4%)	- ()	3 (6%)		
Pigmentation		15 (30%)	31 (63%)	49 (98%)	
Epithelium, Hyperplasia	1 (2%)	7 (14%)	10 (20%)	35 (70%)	
Tongue	(0)	(0)	(0)	(1)	
Tooth	(6)	(9)	(9)	(11)	
Dysplasia	6 (100%)	9 (100%)	9 (100%)	10 (91%)	
	- (· · · · ·)	- (,			
CARDIOVASCULAR SYSTEM					
Blood Vessel	(48)	(50)	(50)	(50)	

Test Type: CHRONIC Route: GAVAGE Species/Strain: MICE/B6C3F1		Time Report Requested: 12:41:17 First Dose M/F: 04/03/07 / 04/02/0 Lab: BAT			
B6C3F1 MICE FEMALE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	
Mineralization			1 (2%)		
Aorta, Inflammation, Chronic				1 (2%)	
Heart	(50)	(50)	(50)	(50)	
Cardiomyopathy Inflammation, Chronic	4 (8%)	3 (6%) 1 (2%)	1 (2%)	2 (4%)	
Artery, Inflammation, Chronic			1 (2%)	1 (2%)	
Myocardium, Mineralization	2 (4%)			1 (2%)	
ENDOCRINE SYSTEM					
Adrenal Cortex	(49)	(50)	(50)	(50)	
Hematopoietic Cell Proliferation	1 (2%)				
Hyperplasia	1 (2%)	1 (2%)			
Inflammation, Chronic	1 (2%)				
Necrosis		1 (2%)		1 (2%)	
Vacuolization Cytoplasmic	1 (2%)	1 (2%)	1 (2%)	, , ,	
Adrenal Medulla	(49)	(50)	(50)	(50)	
Hyperplasia	1 (2%)	1 (2%)	3 (6%)	. ,	
Islets, Pancreatic	(50)	(50)	(50)	(50)	
Hyperplasia	5 (10%)	1 (2%)	4 (8%)	1 (2%)	
Parathyroid Gland	(43)	(48)	(49)	(46)	
Pituitary Gland	(49)	(50)	(50)	(49)	
Cyst		2 (4%)			
Pars Distalis, Hyperplasia	5 (10%)	18 (36%)	6 (12%)	4 (8%)	
Pars Distalis, Vacuolization Cytoplasmic	. ,	. ,	. ,	1 (2%)	
Pars Intermedia, Hyperplasia	1 (2%)				
Thyroid Gland	(50)	(50)	(49)	(50)	
Inflammation, Chronic		·	1 (2%)	·	
Follicle, Hyperplasia				1 (2%)	
GENERAL BODY SYSTEM					
Tissue NOS	(0)	(0)	(1)	(0)	
Inflammation, Chronic		. ,	1 (100%)	. ,	

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Date Report Requested: 06/15/2012

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20006 - 04

Test Type: CHRONIC

Species/Strain: MICE/B6C3F1

Route: GAVAGE

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Indole-3-carbinol

CAS Number: 700-06-1

Date Report Requested: 06/15/2012 Time Report Requested: 12:41:17 First Dose M/F: 04/03/07 / 04/02/07 Lab: BAT

B6C3F1 MICE FEMALE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	
GENITAL SYSTEM					
Clitoral Gland	(49)	(50)	(50)	(50)	
Ovary	(50)	(50)	(50)	(50)	
Angiectasis			1 (2%)	1 (2%)	
Cyst	16 (32%)	15 (30%)	9 (18%)	8 (16%)	
Inflammation, Chronic	1 (2%)		1 (2%)		
Mineralization			1 (2%)		
Thrombosis	2 (4%)		2 (4%)	2 (4%)	
Uterus	(50)	(50)	(50)	(50)	
Inflammation, Suppurative		1 (2%)			
Inflammation, Chronic		4 (8%)			
Metaplasia, Squamous		· · ·	1 (2%)		
Necrosis	1 (2%)		. ,		
Endometrium, Hyperplasia, Cystic	36 (72%)	32 (64%)	30 (60%)	34 (68%)	
HEMATOPOIETIC SYSTEM					
Bone Marrow	(50)	(50)	(50)	(50)	
Lymph Node	(9)	(5)	(6)	(1)	
Lumbar, Ectasia	1 (11%)		. ,		
Lumbar, Hemorrhage			1 (17%)		
Renal, Ectasia	2 (22%)	1 (20%)	2 (33%)		
Lymph Node, Mandibular	(50)	(49)	(50)	(50)	
Lymph Node, Mesenteric	(49)	(49)	(49)	(49)	
Spleen	(50)	(50)	(50)	(50)	
Angiectasis	1 (2%)				
Hematopoietic Cell Proliferation	30 (60%)	30 (60%)	27 (54%)	23 (46%)	
Hyperplasia, Granulocytic			1 (2%)	·	
Hyperplasia, Lymphoid		1 (2%)			
Hyperplasia, Mast Cell				1 (2%)	
Pigmentation, Hemosiderin	1 (2%)				
Lymphoid Follicle, Atrophy		1 (2%)			

Experiment Number: 20006 - 04 Test Type: CHRONIC Route: GAVAGE Species/Strain: MICE/B6C3F1	P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a) Indole-3-carbinol CAS Number: 700-06-1				Date Report Requested: 06/15/2012 Time Report Requested: 12:41:17 First Dose M/F: 04/03/07 / 04/02/07 Lab: BAT
B6C3F1 MICE FEMALE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	
Thymus Atrophy Hyperplasia	(49) 42 (86%)	(50) 40 (80%) 1 (2%)	(50) 40 (80%)	(50) 41 (82%)	
INTEGUMENTARY SYSTEM					
Mammary Gland Inflammation, Chronic	(50) 1 (2%)	(50)	(50)	(50)	
Skin Ulcer Subcutaneous Tissue, Fibrosis	(50) 1 (2%) 1 (2%)	(50)	(50) 1 (2%)	(50)	
Subcutaneous Tissue, Hemorrhage Subcutaneous Tissue, Inflammation, Chronic	()		1 (2%)	1 (2%)	
MUSCULOSKELETAL SYSTEM					
Bone Fibro-Osseous Lesion Fracture	(50) 9 (18%) 1 (2%)	(50) 13 (26%)	(50) 11 (22%)	(50) 17 (34%)	
Skeletal Muscle	(0)	(1)	(2)	(0)	
NERVOUS SYSTEM					
Brain Hemorrhage	(50) 1 (2%)	(50)	(50)	(50)	
Inflammation, Granulomatous Hypothalamus, Compression Meninges, Inflammation, Chronic	2 (4%)	1 (2%)		1 (2%)	
RESPIRATORY SYSTEM	,				
Lung Hemorrhage	(50)	(50)	(50)	(50) 1 (2%)	

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

Indole-3-carbinol CAS Number: 700-06-1 Date Report Requested: 06/15/2012 Time Report Requested: 12:41:17 First Dose M/F: 04/03/07 / 04/02/07 Lab: BAT

B6C3F1 MICE FEMALE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	
Hyperplasia, Lymphoid		1 (2%)			
Inflammation, Chronic		1 (2%)			
Metaplasia, Osseous			1 (2%)		
Thrombosis	1 (2%)				
Alveolar Epithelium, Hyperplasia	1 (2%)	2 (4%)	1 (2%)	2 (4%)	
Alveolus, Infiltration Cellular, Histiocyte	1 (2%)	1 (2%)	1 (2%)	1 (2%)	
Mediastinum, Inflammation, Chronic	1 (2%)				
Nose	(50)	(50)	(50)	(50)	
Foreign Body			1 (2%)	2 (4%)	
Inflammation	4 (8%)	1 (2%)	8 (16%)	39 (78%)	
Nerve, Atrophy			1 (2%)	50 (100%)	
Nerve, Olfactory Epithelium, Atrophy	1 (2%)	1 (2%)			
Olfactory Epithelium, Accumulation, Hyaline Droplet	18 (36%)	27 (54%)	21 (42%)	44 (88%)	
Olfactory Epithelium, Atrophy	1 (2%)	2 (4%)	3 (6%)	45 (90%)	
Olfactory Epithelium, Degeneration			2 (4%)	3 (6%)	
Olfactory Epithelium, Necrosis			2 (4%)		
Olfactory Epithelium, Respiratory Metaplasia	7 (14%)	8 (16%)	16 (32%)	49 (98%)	
Respiratory Epithelium, Accumulation, Hyaline Droplet	47 (94%)	38 (76%)	42 (84%)	50 (100%)	
Respiratory Epithelium, Hyperplasia	32 (64%)	31 (62%)	38 (76%)	50 (100%)	
Respiratory Epithelium, Metaplasia, Squamous	1 (2%)				
Respiratory Epithelium, Necrosis	2 (4%)		1 (2%)		
Trachea	(50)	(50)	(50)	(50)	
SPECIAL SENSES SYSTEM					
Ear	(2)	(0)	(0)	(0)	
Eye	(50)	(50)	(50)	(50)	
Cornea, Inflammation, Chronic	1 (2%)		1 (2%)	1 (2%)	
Lens, Cataract	-	1 (2%)	1 (2%)	1 (2%)	
Harderian Gland	(50)	(50)	(50)	(50)	
Dilatation				6 (12%)	
Hyperplasia	2 (4%)	3 (6%)	5 (10%)	9 (18%)	
Infiltration Cellular, Mononuclear Cell	24 (48%)	18 (36%)	8 (16%)	22 (44%)	

Experiment Number: 20006 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Indole-3-carbinol

CAS Number: 700-06-1

Date Report Requested: 06/15/2012 Time Report Requested: 12:41:17 First Dose M/F: 04/03/07 / 04/02/07 Lab: BAT

B6C3F1 MICE FEMALE	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	
JRINARY SYSTEM					
Kidney	(50)	(50)	(50)	(50)	
Infarct	3 (6%)		1 (2%)		
Metaplasia, Osseous				1 (2%)	
Mineralization	4 (8%)	3 (6%)	4 (8%)		
Nephropathy	24 (48%)	25 (50%)	19 (38%)	20 (40%)	
Artery, Inflammation, Chronic				1 (2%)	
Renal Tubule, Accumulation, Hyaline Droplet				1 (2%)	
Renal Tubule, Cyst			1 (2%)	1 (2%)	
Renal Tubule, Pigmentation	1 (2%)				
Urinary Bladder	(50)	(50)	(50)	(50)	
Infiltration Cellular, Mononuclear Cell	3 (6%)				
Transitional Epithelium, Hyperplasia				1 (2%)	

*** END OF REPORT ***